Philip Tagari

About Philip Tagari

Philip Tagari is currently Chief Scientific Officer and Head of R&D (interim) of insitro, a leading AI – Drug Discovery company. His team of multidisciplinary scientists and engineers are redefining disease biology and implementing AI approaches to dramatically speed the delivery of meaningful therapeutics to patients with grievous disease. Prior to insitro, Philip spent over a decade as Vice President of Research (Therapeutic Discovery) at Amgen Inc. During that time, his global teams advanced over 35 innovative molecules into clinical development and commercialization most recently including Imdelltra® (first-in class (DLL3 BiTE®); Lumakras® (first-in-class KRASG12C inhibitor); Maritide® (anti-obesity bispecific) and Tezpire® (first-in-class TSLP blocker). He is a Director of CQDM (Consortium Quebecois sur la Decouverte du Medicament; Quebec Consortium for Drug Discovery), SAB member for BenchSci (biology machine learning) and a Bessemer Ventures operating advisor.Prior to joining Amgen in 1998, Philip was a Research Fellow at Merck Frosst (Canada) Inc, where he contributed to the discovery of Singulair® and Vioxx®. Philip is a graduate of Gonville & Caius College, Cambridge University (UK), and performed neurobiology research using pioneering quantitative image analysis at McGill and Oxford Universities.

Experience

1. CSO Insitro

   insitro

   Feb 2023 — Present · San Francisco, CA, US

Education

• Gonville & Caius College, Cambridge University

  MA, Natural Sciences

  1976 — 1979

Skills

• Cell Biology
• Biologics
• Signal Transduction
• Pharmacology
• Molecular Biology
• Immunology
• Clinical Development
• Biochemistry
• Corporate Venture Capital
• Licensing
• Analytical Chemistry
• Biopharmaceuticals
• Biotechnology
• Drug Discovery